TADA3

Across TCGA pan-cancer cohorts, TADA3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of TADA3’s most consistent transcriptional readouts.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where TADA3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types TADA3 is over-expressed in tumor, although a few such as CCRCC show the opposite, repressed pattern.

LSCC, LUAD, and CCRCC are the cancer types where TADA3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in TADA3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
LSCC	Female	All	+0.191	<.001	6	view →
LUAD	Male	II,III,IV	+0.137	<.001	5	view →
CCRCC	All	All	−0.063	.012	2	view →
COAD	All	III,IV	+0.301	.046	1	view →
HNSC	All	IV	+0.157	.030	1	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

TADA3–LSCC

Open the LSCC breakdown →